We are a clinical research site founded in 2001 by Stephen Flitman, MD, a board-certified neurologist who trained at the Barrow Neurological Institute (Phoenix, Arizona) and completed his fellowship in Cognitive Neuroscience at the prestigious National Institutes of Health (Bethesda, Maryland). He served as first Associate Director then Director of Cognitive Neurology Section at Barrow until 2001.

Joshua Tobin, MD joined in 2006 and added expertise in Migraine and atypical headache, leaving after a distinguished career spanning 15 years. In 2021, Kathleen Callahan, PA-C joined the practice and has been invaluable in extending our mission and availability to our patients.

We have been involved in over 200 clinical trials across the gamut of neurological disease and have contributed to the approvals of many drugs.

These are the treatments which Xenoscience has helped to develop over the years which were eventually approved by the US Food and Drug Administration (FDA). Most have also been approved by the EU equivalent agency, European Medicines Agency.

• Aduhelm
• Aricept
• Axona
• Exelon
• Exelon Patch
• Leqembi
• Razadyne
• Razadyne ER

• Aptiom
• Briviact
• Fycompa
• Keppra IV
• Oxtellar XR
• Vimpat
• Xcopri

• Cymbalta
• Lyrica
• Savella

• Emgality
• Pediatric Maxalt MLT
• Reyvow
• Ubrelvy

• Aubagio
• Gilenya
• Ocrevus
• Plegridy
• Tecfidera
• Vumerity
• Zeposia

• Lyrica for Diabetic Neuropathy Pain
• Qutenza for HIV Neuropathy Pain

• Nourianz to improve motor function
• Stalevo to improve motor function

A sobering thought: For every drug that is successfully brought to the US market, many more (sometimes as many as hundreds more) have failed in clinical trials.